%0 Journal Article
%T The efficacy and safety of febuxostat for urate lowering in gout patients ¡Ý65 years of age
%A Robert L Jackson
%A Barbara Hunt
%A Patricia A MacDonald
%J BMC Geriatrics
%D 2012
%I BioMed Central
%R 10.1186/1471-2318-12-11
%X Hyperuricemic (serum urate [sUA] levels ¡Ý 8.0 mg/dL) gout subjects were enrolled in the 6-month, double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80 mg, or allopurinol (200 mg or 300 mg based on renal function) once daily. Flare prophylaxis was provided throughout the study duration.Study endpoints were the percent of elderly subjects with sUA <6.0 mg/dL at the final visit, overall and by renal function status, percent change in sUA from baseline to final visit, flare rates, and rates of adverse events (AEs).Of 2,269 subjects enrolled, 374 were elderly. Febuxostat 80 mg was significantly more efficacious (82.0%) than febuxostat 40 mg (61.7%; p < 0.001) or allopurinol (47.3%; p < 0.001) for achieving the primary efficacy endpoint. Febuxostat 40 mg was also superior to allopurinol in this population (p = 0.029). In subjects with mild-to-moderate renal impairment, significantly greater ULT efficacy was observed with febuxostat 40 mg (61.6%; p = 0.028) and febuxostat 80 mg (82.5%; p < 0.001) compared to allopurinol 200/300 mg (46.9%). Compared to allopurinol 200/300 mg, the mean percent change in sUA from baseline was significantly greater for both febuxostat 80 mg (p < 0.001) and febuxostat 40 mg (p = 0.011) groups. Flare rates declined steadily in all treatment groups. Rates of AEs were low and comparable across treatments.These data suggest that either dose of febuxostat is superior to commonly prescribed fixed doses of allopurinol (200/300 mg) in subjects ¡Ý65 years of age with high rates of renal dysfunction. In addition, in this high-risk population, ULT with either drug was well tolerated.clinicaltrials.gov NCT#00430248The average age of patients seeking care for gout in the United States is approximately 66 years [1]. Managing gout in the elderly (¡Ý65 years of age) is clinically challenging as people in this demographic segment have lower creatinine clearance, a greater frequency of comorbidities, and are
%U http://www.biomedcentral.com/1471-2318/12/11